Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Papamichail

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|November 29, 2016
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptideIoannis F Voutsas, Eleftheria A Anastasopoulou, Panagiotis Tzonis, et al.
Haematologica|March 1, 2002
Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cellsNike T Cacoullos, Angelos D Gritzapis, Athanasios E Tsitsilonis, et al.
Cancer Research|May 19, 2006
Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivoAngelos D Gritzapis, Louisa G Mahaira, Sonia A Perez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2011
NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responsesMaria Salagianni, Eftychia Lekka, Ardiana Moustaki, et al.
Breast Cancer Research and Treatment|August 2, 2003
Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assayAngelos D Gritzapis, Constantin N Baxevanis, Ioannis Missitzis, et al.
Vaccine|October 6, 2009
HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor propertiesAngelos D Gritzapis, Arthur Fridman, Sonia A Perez, et al.
Cellular Immunology|July 19, 2005
Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and functionNectaria N Sotiriadou, Sonia A Perez, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2003
In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RIAvgi Mamalaki, Angelos D Gritzapis, Androniki Kretsovali, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2009
Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyEftychia Lekka, Angelos D Gritzapis, Sonia A Perez, et al.
Journal of Immunological Methods|June 22, 2007
A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GRIoannis F Voutsas, Angelos D Gritzapis, Michael N Alexis, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|November 29, 2016
Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptideIoannis F Voutsas, Eleftheria A Anastasopoulou, Panagiotis Tzonis, et al.
Haematologica|March 1, 2002
Efficacy of novel culture environments on the ex vivo expansion kinetics of cord blood progenitor cellsNike T Cacoullos, Angelos D Gritzapis, Athanasios E Tsitsilonis, et al.
Cancer Research|May 19, 2006
Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivoAngelos D Gritzapis, Louisa G Mahaira, Sonia A Perez, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 15, 2011
NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responsesMaria Salagianni, Eftychia Lekka, Ardiana Moustaki, et al.
Breast Cancer Research and Treatment|August 2, 2003
Quantitative fluorescence cytometric measurement of estrogen and progesterone receptors: correlation with the hormone binding assayAngelos D Gritzapis, Constantin N Baxevanis, Ioannis Missitzis, et al.
Vaccine|October 6, 2009
HER-2/neu (657-665) represents an immunogenic epitope of HER-2/neu oncoprotein with potent antitumor propertiesAngelos D Gritzapis, Arthur Fridman, Sonia A Perez, et al.
Cellular Immunology|July 19, 2005
Beneficial effect of short-term exposure of human NK cells to IL15/IL12 and IL15/IL18 on cell apoptosis and functionNectaria N Sotiriadou, Sonia A Perez, Angelos D Gritzapis, et al.
Cancer Immunology, Immunotherapy : CII|April 26, 2003
In vitro and in vivo antitumor activity of a mouse CTL hybridoma expressing chimeric receptors bearing the single chain Fv from HER-2/neu- specific antibody and the gamma-chain from Fc(epsilon) RIAvgi Mamalaki, Angelos D Gritzapis, Androniki Kretsovali, et al.
Cancer Immunology, Immunotherapy : CII|November 12, 2009
Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapyEftychia Lekka, Angelos D Gritzapis, Sonia A Perez, et al.
Journal of Immunological Methods|June 22, 2007
A novel quantitative flow cytometric method for measuring glucocorticoid receptor (GR) in cell lines: correlation with the biochemical determination of GRIoannis F Voutsas, Angelos D Gritzapis, Michael N Alexis, et al.
Pageof 7